Which has better earnings & valuation, ANAB or CGON?

AnaptysBio has higher revenue and earnings than CG Oncology. AnaptysBio is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AnaptysBio $232.39M 7.45 -$13.23M -$1.08 N/A CG Oncology $4.04M 1,646.20 -$160.99M -$2.69 N/A

Is ANAB or CGON more profitable?

AnaptysBio has a net margin of -11.53% compared to CG Oncology's net margin of -3,602.68%. AnaptysBio's return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets AnaptysBio -11.53% N/A -7.75% CG Oncology -3,602.68% -26.58% -25.34%

Does the media refer more to ANAB or CGON?

In the previous week, CG Oncology had 13 more articles in the media than AnaptysBio. MarketBeat recorded 16 mentions for CG Oncology and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.63 beat CG Oncology's score of 0.13 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor MIRM or ANAB?

In the previous week, Mirum Pharmaceuticals had 25 more articles in the media than AnaptysBio. MarketBeat recorded 28 mentions for Mirum Pharmaceuticals and 3 mentions for AnaptysBio. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat AnaptysBio's score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XENE or ANAB?

In the previous week, Xenon Pharmaceuticals had 22 more articles in the media than AnaptysBio. MarketBeat recorded 25 mentions for Xenon Pharmaceuticals and 3 mentions for AnaptysBio. Xenon Pharmaceuticals' average media sentiment score of 0.75 beat AnaptysBio's score of 0.63 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNTH or ANAB?

In the previous week, Dianthus Therapeutics had 29 more articles in the media than AnaptysBio. MarketBeat recorded 32 mentions for Dianthus Therapeutics and 3 mentions for AnaptysBio. Dianthus Therapeutics' average media sentiment score of 0.63 beat AnaptysBio's score of 0.63 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 10 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ANAB or LGND?

In the previous week, Ligand Pharmaceuticals had 8 more articles in the media than AnaptysBio. MarketBeat recorded 11 mentions for Ligand Pharmaceuticals and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.63 beat Ligand Pharmaceuticals' score of 0.57 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AnaptysBio (ANAB) Competitors

$58.47 +2.45 (+4.37%)

Closing price 04:00 PM Eastern

Extended Trading

$58.42 -0.05 (-0.09%)

As of 05:59 PM Eastern

Compare

ANAB vs. CGON, MIRM, XENE, DNTH, and LGND

Should you buy AnaptysBio stock or one of its competitors? AnaptysBio's main competitors and comparable companies include CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), Dianthus Therapeutics (DNTH), and Ligand Pharmaceuticals (LGND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AnaptysBio compare to CG Oncology?

AnaptysBio (NASDAQ:ANAB) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

AnaptysBio has a net margin of -11.53% compared to CG Oncology's net margin of -3,602.68%. AnaptysBio's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
CG Oncology	-3,602.68%	-26.58%	-25.34%

26.6% of CG Oncology shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AnaptysBio has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

AnaptysBio has higher revenue and earnings than CG Oncology. AnaptysBio is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$232.39M	7.45	-$13.23M	-$1.08	N/A
CG Oncology	$4.04M	1,646.20	-$160.99M	-$2.69	N/A

In the previous week, CG Oncology had 13 more articles in the media than AnaptysBio. MarketBeat recorded 16 mentions for CG Oncology and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.63 beat CG Oncology's score of 0.13 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

AnaptysBio presently has a consensus target price of $82.00, suggesting a potential upside of 40.24%. CG Oncology has a consensus target price of $83.18, suggesting a potential upside of 10.86%. Given AnaptysBio's higher probable upside, research analysts plainly believe AnaptysBio is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

AnaptysBio beats CG Oncology on 10 of the 16 factors compared between the two stocks.

How does AnaptysBio compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

AnaptysBio has a net margin of -11.53% compared to Mirum Pharmaceuticals' net margin of -139.18%. AnaptysBio's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
AnaptysBio	-11.53%	N/A	-7.75%

In the previous week, Mirum Pharmaceuticals had 25 more articles in the media than AnaptysBio. MarketBeat recorded 28 mentions for Mirum Pharmaceuticals and 3 mentions for AnaptysBio. Mirum Pharmaceuticals' average media sentiment score of 0.64 beat AnaptysBio's score of 0.63 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

AnaptysBio has lower revenue, but higher earnings than Mirum Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.53	-$23.36M	-$14.55	N/A
AnaptysBio	$232.39M	7.45	-$13.23M	-$1.08	N/A

Mirum Pharmaceuticals currently has a consensus target price of $137.33, suggesting a potential upside of 36.46%. AnaptysBio has a consensus target price of $82.00, suggesting a potential upside of 40.24%. Given AnaptysBio's higher probable upside, analysts clearly believe AnaptysBio is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Mirum Pharmaceuticals beats AnaptysBio on 8 of the 15 factors compared between the two stocks.

How does AnaptysBio compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Xenon Pharmaceuticals has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%
AnaptysBio	-11.53%	N/A	-7.75%

Xenon Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.9% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 31.5% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xenon Pharmaceuticals had 22 more articles in the media than AnaptysBio. MarketBeat recorded 25 mentions for Xenon Pharmaceuticals and 3 mentions for AnaptysBio. Xenon Pharmaceuticals' average media sentiment score of 0.75 beat AnaptysBio's score of 0.63 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xenon Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AnaptysBio has higher revenue and earnings than Xenon Pharmaceuticals. AnaptysBio is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	$7.50M	803.65	-$345.91M	-$4.74	N/A
AnaptysBio	$232.39M	7.45	-$13.23M	-$1.08	N/A

Xenon Pharmaceuticals presently has a consensus target price of $77.13, suggesting a potential upside of 23.71%. AnaptysBio has a consensus target price of $82.00, suggesting a potential upside of 40.24%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Xenon Pharmaceuticals beats AnaptysBio on 9 of the 17 factors compared between the two stocks.

How does AnaptysBio compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and AnaptysBio (NASDAQ:ANAB) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

In the previous week, Dianthus Therapeutics had 29 more articles in the media than AnaptysBio. MarketBeat recorded 32 mentions for Dianthus Therapeutics and 3 mentions for AnaptysBio. Dianthus Therapeutics' average media sentiment score of 0.63 beat AnaptysBio's score of 0.63 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	10 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AnaptysBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dianthus Therapeutics presently has a consensus price target of $124.27, suggesting a potential upside of 7.17%. AnaptysBio has a consensus price target of $82.00, suggesting a potential upside of 40.24%. Given AnaptysBio's higher probable upside, analysts plainly believe AnaptysBio is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

AnaptysBio has higher revenue and earnings than Dianthus Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	3,107.61	-$162.34M	-$4.15	N/A
AnaptysBio	$232.39M	7.45	-$13.23M	-$1.08	N/A

AnaptysBio has a net margin of -11.53% compared to Dianthus Therapeutics' net margin of -10,096.95%. AnaptysBio's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
AnaptysBio	-11.53%	N/A	-7.75%

Summary

Dianthus Therapeutics beats AnaptysBio on 9 of the 17 factors compared between the two stocks.

How does AnaptysBio compare to Ligand Pharmaceuticals?

AnaptysBio (NASDAQ:ANAB) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Ligand Pharmaceuticals has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$232.39M	7.45	-$13.23M	-$1.08	N/A
Ligand Pharmaceuticals	$268.09M	21.91	$124.45M	$9.35	31.51

In the previous week, Ligand Pharmaceuticals had 8 more articles in the media than AnaptysBio. MarketBeat recorded 11 mentions for Ligand Pharmaceuticals and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.63 beat Ligand Pharmaceuticals' score of 0.57 indicating that AnaptysBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AnaptysBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has a net margin of 67.88% compared to AnaptysBio's net margin of -11.53%. Ligand Pharmaceuticals' return on equity of 20.06% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

AnaptysBio currently has a consensus target price of $82.00, indicating a potential upside of 40.24%. Ligand Pharmaceuticals has a consensus target price of $335.75, indicating a potential upside of 13.97%. Given AnaptysBio's higher possible upside, research analysts plainly believe AnaptysBio is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

AnaptysBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats AnaptysBio on 12 of the 15 factors compared between the two stocks.

Get AnaptysBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANAB vs. The Competition

Export

Metric	AnaptysBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.73B	$3.71B	$6.97B	$13.05B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-54.14	10.68	269.86	25.30
Price / Sales	7.45	1,307.84	602.27	101.40
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	43.63	17.49	13.08	6.33
Net Income	-$13.23M	-$13.32M	$3.45B	$347.70M
7 Day Performance	3.29%	1.74%	1.12%	1.07%
1 Month Performance	-6.46%	1.60%	1.79%	1.03%
1 Year Performance	192.79%	56.43%	67.69%	20.77%

AnaptysBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANAB AnaptysBio	2.2581 of 5 stars	$58.47 +4.4%	$82.00 +40.2%	+170.4%	$1.73B	$232.39M	N/A	100
CGON CG Oncology	2.5113 of 5 stars	$72.42 +1.4%	$81.73 +12.9%	+182.0%	$6.39B	$5.07M	N/A	61
MIRM Mirum Pharmaceuticals	3.5252 of 5 stars	$105.79 +1.4%	$143.40 +35.6%	+51.6%	$6.36B	$569.61M	N/A	140	Insider Trade Analyst Revision
XENE Xenon Pharmaceuticals	3.0234 of 5 stars	$64.30 +0.5%	$77.20 +20.1%	+70.5%	$6.19B	$7.50M	N/A	210	Insider Trade Analyst Revision
DNTH Dianthus Therapeutics	1.9221 of 5 stars	$112.50 +1.9%	$120.09 +6.7%	+425.7%	$6.04B	$1.34M	N/A	80	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANAB) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AnaptysBio (ANAB) Competitors

ANAB vs. CGON, MIRM, XENE, DNTH, and LGND

How does AnaptysBio compare to CG Oncology?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Summary

How does AnaptysBio compare to Xenon Pharmaceuticals?

Summary

How does AnaptysBio compare to Dianthus Therapeutics?

Summary

How does AnaptysBio compare to Ligand Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AnaptysBio (ANAB) Competitors

ANAB vs. CGON, MIRM, XENE, DNTH, and LGND

How does AnaptysBio compare to CG Oncology?

Is ANAB or CGON more profitable?

Do insiders and institutionals hold more shares of ANAB or CGON?

Which has more risk & volatility, ANAB or CGON?

Which has better earnings & valuation, ANAB or CGON?

Does the media refer more to ANAB or CGON?

Do analysts rate ANAB or CGON?

Summary

How does AnaptysBio compare to Mirum Pharmaceuticals?

Is MIRM or ANAB more profitable?

Does the media favor MIRM or ANAB?

Which has more volatility and risk, MIRM or ANAB?

Which has preferable valuation and earnings, MIRM or ANAB?

Do analysts recommend MIRM or ANAB?

Summary

How does AnaptysBio compare to Xenon Pharmaceuticals?

Is XENE or ANAB more profitable?

Which has more risk and volatility, XENE or ANAB?

Do insiders & institutionals believe in XENE or ANAB?

Does the media favor XENE or ANAB?

Which has preferable valuation and earnings, XENE or ANAB?

Do analysts rate XENE or ANAB?

Summary

How does AnaptysBio compare to Dianthus Therapeutics?

Does the media favor DNTH or ANAB?

Which has more volatility & risk, DNTH or ANAB?

Do institutionals and insiders hold more shares of DNTH or ANAB?

Do analysts recommend DNTH or ANAB?

Which has preferable earnings & valuation, DNTH or ANAB?

Is DNTH or ANAB more profitable?

Summary

How does AnaptysBio compare to Ligand Pharmaceuticals?

Which has preferable valuation and earnings, ANAB or LGND?

Does the media refer more to ANAB or LGND?

Do insiders & institutionals have more ownership in ANAB or LGND?

Is ANAB or LGND more profitable?

Do analysts rate ANAB or LGND?

Which has more volatility and risk, ANAB or LGND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAB vs. The Competition

AnaptysBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools